UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 56,859 Shares of Alkermes plc (NASDAQ:ALKS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 14.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 462,241 shares of the company's stock after acquiring an additional 56,859 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.29% of Alkermes worth $13,294,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Barclays PLC raised its stake in shares of Alkermes by 108.8% during the third quarter. Barclays PLC now owns 423,931 shares of the company's stock valued at $11,867,000 after acquiring an additional 220,893 shares during the last quarter. Blue Trust Inc. increased its holdings in Alkermes by 2,394.5% during the 4th quarter. Blue Trust Inc. now owns 1,821 shares of the company's stock valued at $51,000 after purchasing an additional 1,748 shares during the period. KBC Group NV raised its position in Alkermes by 46.7% during the 4th quarter. KBC Group NV now owns 7,176 shares of the company's stock valued at $206,000 after purchasing an additional 2,286 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in Alkermes by 28.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 122,489 shares of the company's stock worth $3,523,000 after buying an additional 26,980 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Alkermes by 8.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 34,308 shares of the company's stock worth $987,000 after buying an additional 2,637 shares during the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ALKS. HC Wainwright reaffirmed a "neutral" rating on shares of Alkermes in a research note on Friday, May 2nd. Royal Bank of Canada lifted their target price on shares of Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Cantor Fitzgerald raised shares of Alkermes to a "strong-buy" rating in a research note on Tuesday, May 13th. Wall Street Zen cut Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 5th. Finally, Needham & Company LLC began coverage on Alkermes in a research report on Wednesday, May 28th. They issued a "buy" rating and a $45.00 target price for the company. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.85.

Alkermes Trading Down 0.1%

Shares of ALKS stock traded down $0.02 during trading hours on Tuesday, reaching $31.27. 1,143,718 shares of the stock were exchanged, compared to its average volume of 1,756,058. The firm has a market capitalization of $5.16 billion, a price-to-earnings ratio of 14.41, a price-to-earnings-growth ratio of 2.20 and a beta of 0.51. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The company's 50-day moving average price is $29.71 and its 200-day moving average price is $30.89.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The business had revenue of $306.51 million for the quarter, compared to analysts' expectations of $307.53 million. During the same quarter in the previous year, the firm earned $0.43 EPS. Alkermes's revenue was down 12.6% compared to the same quarter last year. On average, sell-side analysts expect that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.